Microsoft word - 02_congresso di ipertermia_ungheria_abstract pigliucci_corr300712_giulia

STABILIZATION OF METASTATIC BREAST CANCER WITH CAPACITIVE 
HYPERTHERMIA PLUS STANDARD‐DOSE CHEMOTHERAPY AND/OR METRONOMIC 
CHEMOTHERAPY 

Coletta D1., Gargano L.1, Assogna M.1, Castigliani G.1, De Chicchis M.1,. Gabrielli F. 2 , Mauro F.
2, Pantaleoni G.2 and Pigliucci G.M1.
1. Department of Oncological Hyperthermia. University of Tor Vergata. Rome. Italy.
2. Interfaculty Department for Scientific Research (D.I.R.S).- L.U.de.S. University. Lugano –
Switzerland.
In our long experience in Universitary Hyperthermia treatment of tumors associated with
chemotherapy, we observed that response to associated treatment determines the disease
stabilization and significant clinical benefits for 24 months in 12 cases of metastatic breast cancer,
whereas chemotherapy alone had shown ineffective with disease progression, bone marrow toxicity
G3-4, fatigue G2-3, nausea and vomiting G1-G2, bone pain G3-4 and visceral pain G2-3. (Table 1).
2 out of 12 patients underwent hormone therapy alone because they were allergic to chemotherapy
drugs, other 10 patients underwent CHT+/- Hormone Therapy according to the protocols seen in
Table 2.
TOXICITY WITH CHT ALONE
TOXICITY WITH ASSOCIATED THERAPIES
(CHT+HT)
CMF, Docetaxel, Nolvadex, Enantone Trastuzumab+CBDCA, Myocet+Gemcitabine FEC, Trastuzumab, Vinorelbine, Capecitabine, Fulvestrant Myocet+ Docetaxel, Myocet+Gemcitabine, Zoledronic Acid Fulvestrant+Xeloda, CBDCA+TAX, NVB+GEM Xeloda+TXT+BEVA,CBDCA+GEM, TAXOL, NVB, Myocet Herceptin+CBDCA, Myocet+Gemcitabina FEC,CBDCA+GEM, Herceptin+NVB, Lapatinib+Xeloda All patients underwent on average 30 cycles of capacitive hyperthermia, each consisting of eight
daily 45-minute sessions, using 300W per session.
In these patients the improvement of performance status has allowed a return to regular life. This
improvement of the quality of life showed a correspondent biochemical response, with a
progressive reduction in tumour markers and showed also a diagnostic response with stabilization
of the disease: in some cases reduction of size and/or number of metastases and in all cases with
absence of metabolic activity disease (TB PET CT scan).
According to the studies on P.N.E.I.M (1, 6, 7), the results in the field of Clinical Pharmacology
concerning drug abuse and medicines disuse, and the resulting recent studies in anthropology on
cancer patients, all of our patients were treated at a preventive, therapeutic and post-treatment level
with appropriate behavioural tests and drug treatments to avoid relapse. Clinical Pharmacology, in
our opinion, considers every patient, following the multidimensional (bio-psychosocial) approach,
as a global being (8, 9, 10, 11).
REFERENCES:
1. Multidisciplinary therapy for 984 cancer patients;-hyperthermic immunotherapy. Takeda T, Miyazawa K, Takeda T, Takeda H, Takeda Y. Osaka Cancer Immuno-Chemotherapy Center. 2. Durable palliation of breast cancer chest wall recurrence with radiation therapy, Zagar TM, Higgins KA, Miles EF, Vujaskovic Z, Dewhirst MW, Clough RW, Prosnitz LR, Jones EL. Radiother Oncol. 2010 Dec;97(3):535-40. Epub 2010 Nov 11. 3. Reirradiation combined with hyperthermia in breast cancer recurrences: overview of Van Der Zee J, De Bruijne M, Mens JW, Ameziane A, Broekmeyer-Reurink MP, Drizdal T, Linthorst M, Van Rhoon GC. Int J Hyperthermia. 2010; 26(7):638-48. Review. 4. Hyperthermia for locally advanced breast cancer. Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL. Int J Hyperthermia. 2010;26(7):618-24. Review. 5. Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced Franchi F, Grassi P, Ferro D, Pigliucci GM, De Chicchis M, Castigliani G, Pastore C, Seminara P. Eur J Cancer Care (Engl). 2007 May; 16(3):258-62. 6. Immunomodulation, Brain Areas Involved. Danuta Wrona., Encyclopedia of Neuroscience, 7. Neuroendocrine modulation of the immune system: Possible implications for inflammatory bowel disease. Fergus Shanahan and Peter Anton. Digestive diseases and sciences. Volume 33, Supplement 3 (1988), 41S-49S, 8. The Holistic Claims of the Biopsychosocial Conception of WHO’s International Classification of Functioning, Disability, and Health (ICF): A Conceptual Analysis on the Basis of a Pluralistic–Holistic Ontology and Multidimensional View of the Human being. Hans Magnus Solli and António Barbosa da Silva. J Med Philos first published online May 7, 2012 doi:10.1093/jmp/jhs014. 9. Self-criticism, neediness, and distress among women undergoing treatment for breast cancer: A preliminary test of the moderating role of adjustment to illness. Campos, Rui C.; Besser, Avi; Ferreira, Raquel; Blatt, Sidney J. International Journal of Stress Management, Vol 19(2), May 2012, 151-174. doi: 10.1037/a0027996 10. The psychological impact of mammographic screening. A systematic review. J. Brett, C. Bankhead, B. Henderson, E. Watson, and J. Austoker Psycho-Oncology, vol. 14, no. 11, pp. 917–938, 2005. 11. Anxiety, emotional suppression, and psychological distress before and after breast cancer Y. Iwamitsu, K. Shimoda, H. Abe, T. Tani, M. Okawa, and R. Buck Psychosomatics, vol. 46, no. 1, pp. 19–24, 2005.

Source: http://www.synchrotherm.com/pdf2012/STUDI_CLINICI/METASTATIC_BREAST_CANCER.pdf